Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 18/20 | 0.51 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.51 |
| ▸ | AGTR2 | P50052 | 10/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8477037 | 1.00 | AGTR1 (0.51) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL2477 | 0.93 | AGTR1 (0.46) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL8477555 | 0.91 | AGTR1 (0.44) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL8477688 | 0.91 | AGTR1 (0.50) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL8524093 | 0.91 | AGTR1 (0.50) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL2439774 | 0.90 | AGTR1 (0.48) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL2529 | 0.90 | AGTR1 (0.53) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL14958522 | 0.90 | AGTR1 (0.44) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL2692 | 0.90 | AGTR1 (0.44) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL30929307 | 0.87 | AGTR1 (0.41) | AGTR1LTB4R2ABCB11GP6AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11642329-B2 | Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2023-05-09 | — | — | US | claimed |
| US-20220331282-A1 | AMORPHOUS SOLID FORM OF COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND SODIUM CATIONS | NOVARTIS PHARMACECUTICALS CORPORATION | 2022-10-20 | — | — | US | claimed |
| US-20220257551-A1 | AMORPHOUS SOLID FORM OF COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND SODIUM CATIONS | NOVARTIS PHARMACEUTICALS CORPORATION | 2022-08-18 | — | — | US | claimed |
| US-20220133694-A1 | PHARMACEUTICAL USE | NOVARTIS PHARMACEUTICALS CORPORATION | 2022-05-05 | — | — | US | claimed |
| US-20210361610-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | NOVARTIS PHARMACEUTICALS CORPORATION | 2021-11-25 | — | — | US | claimed |
| US-20200276166-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | UNIV CALIFORNIA (US) | 2020-09-03 | — | — | US | claimed |
| EP-3685833-A1 | COMPOUND COMPRISING AN ARB AND A NEPI | Novartis AG (CH) | 2020-07-29 | — | — | EP | claimed |
| US-20200016109-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | NOVARTIS AG (CH) | 2020-01-16 | — | — | US | claimed |
| WO-2017154017-A1 | PROCESS FOR THE PREPARATION OF TRISODIUM (4-{[1S,3R)-1-([1,1'-BIPHENYL]-4-YLMETHYL)-4-ETHOXY-3-METHYL-4-OXOBUTYL]AMINO}-4-OXOBUTANOATE)-(N-PENTANOYL-N-{[2'-(1H-TETRAZOL-1-ID-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL}- L-VALINATE) AND ITS POLYMORPHS THEREOF | MSN LABORATORIES LIMITED (IN) | 2017-09-14 | — | — | WO | claimed |
| US-20160367530-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-12-22 | — | — | US | claimed |
| EP-1948158-B1 | PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR | NOVARTIS AG (CH) | 2014-01-29 | — | — | EP | claimed |
| US-20120058949-A1 | Methods of Treating Neurological Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2012-03-08 | — | — | US | claimed |
| EP-2340828-A1 | Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor | Novartis AG (CH) | 2011-07-06 | — | — | EP | claimed |
| WO-2010065917-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-06-10 | — | — | WO | claimed |
| US-20090156585-A1 | ORGANIC COMPOUNDS | NOVARTIS PHARMACEUTICALS CORPORATION | 2009-06-18 | — | — | US | claimed |
| EP-1393722-A2 | Use of angiotensin II subtype 1 (AT1) antagonists for the manufacture of a medicament in the treatment of premenstrual syndrome | DePadova, Anthony S. (US) | 2004-03-03 | — | — | EP | claimed |
| EP-0759754-A4 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DEPADOVA ANTHONY S (US) | 2000-07-05 | — | — | EP | claimed |
| US-5753651-A | Use of AT1 antagonist such as irbesartan or candesartan cilexetil, among others; premenstrual syndrome (PMS) | DEPADOVA ANTHONY S (US) | 1998-05-19 | — | — | US | claimed |
| EP-0759754-A1 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DePadova, Anthony S. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1995029674-A1 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DEPADOVA ANTHONY S (US) | 1995-11-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133694-A1 | PHARMACEUTICAL USE | TNNT2, TNNI3, NPPA | AGTR1 1236/4885LTB4R2 1417/4885ABCB11 14/4885 |
| US-20210361610-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | MME, DNPEP, ANPEP | AGTR1 4/4885LTB4R2 1393/4885ABCB11 1638/4885 |
| US-20220331282-A1 | AMORPHOUS SOLID FORM OF COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND SODIUM CATIONS | MME, DNPEP, AGTR1 | AGTR1 3/4885LTB4R2 2298/4885ABCB11 2470/4885 |
| US-11642329-B2 | Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations | MME, DNPEP, AGTR1 | AGTR1 3/4885LTB4R2 2312/4885ABCB11 1883/4885 |
| US-20220257551-A1 | AMORPHOUS SOLID FORM OF COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND SODIUM CATIONS | MME, DNPEP, AGTR1 | AGTR1 3/4885LTB4R2 2298/4885ABCB11 2470/4885 |
| US-20090156585-A1 | ORGANIC COMPOUNDS | REN, AGTR1, AGTR2 | AGTR1 2/4885LTB4R2 310/4885ABCB11 1222/4885 |
| US-20200016109-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | MME, DNPEP, ANPEP | AGTR1 4/4885LTB4R2 1393/4885ABCB11 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.